Allarity Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Allarity Therapeutics, Inc. (ALLR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 75.00 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-30
- Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 0.00 shares.
- Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 75.00K shares.
- Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 75.00K shares.
- Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 46.00K shares, a 95.52% decline from fiscal 2021.
- Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 1.03M shares, a 1414.44% increase from fiscal 2020.
- Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 67.79K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-30 | 0.00 shares derived: sum of 3 quarters · filed 2026-03-30 | 75.00K shares 10-K · filed 2026-03-30 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-14 | 75.00K shares 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | 75.00K shares 10-Q · filed 2025-08-15 | |||
| 2025-03-31 | 75.00K shares 10-Q · filed 2025-05-09 | ||||
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | 23.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | 46.00K shares 10-K · filed 2023-03-13 | |||
| 2022-09-30 | 23.00K shares 10-Q · filed 2022-11-14 | ||||
| 2021-12-31 | 1.03M shares 10-K · filed 2022-05-17 | ||||
| 2020-12-31 | 67.79K shares 10-Q/A · filed 2022-05-17 | 3.39M shares 10-Q · filed 2021-11-23 | 67.79K shares 10-K · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |